While Lonza's biopharmaceutical business has taken off, tough
competition from cheap Asian competitors is eating away at its
exclusive synthesis business - meanwhile, the whole business is
being hit by rising raw material and...
Lonza has been authorised by the US Food and Drug Administration
(FDA) to produce Bristol-Myers Squibb's arthritis drug Orencia
(abatacept), in what is shaping up to be a major manufacturing deal
for the Swiss company.
Chemicals firm Lonza has vowed to spend $200m (€160m) over the next
few years to expand in southern China, further limiting its
dependence on external suppliers of intermediates and active
pharmaceutical ingredients (APIs).
Swiss custom manufacturing firm Lonza has entered into a joint
venture with investment management company Bio*One Capital to built
a $250m (€210m) large-scale mammalian cell culture plant in
Singapore, underlying Lonza's confidence...
Swiss outsourcing company Lonza has granted biotechnology firm
Genentech a non-exclusive, worldwide license to their Glutamine
Synthetase (GS) Gene Expression System which offers better yields,
speed and stability in cell protein...
Switzerland's Lonza has boosted its ability to make active
pharmaceutical ingredients (API) at its Visp site in response to
what it said was 'ever increasing hygienic and regulatory
requirements'.
Swiss chemicals firm and contract manufacturer Lonza fulfilled its
promise of stronger financial results in the first half of 2005,
with profits coming in at the lower end of the forecast range, but
still on target, reports Phil Taylor.
Lonza has started a SF 14 million (€9m) expansion of its biologics
manufacturing facility in Slough, UK, in response to what it said
was increasing demand for mammalian cell production for clinical
trials, reports Phil Taylor.
Lonza is planning a major exansion of its peptides manufacturing
capacities at Visp, Switzerland, in response to what it said was
'the increased demand for peptide active pharmaceutical ingredients
worldwide'.
Swiss chemicals and contract manufacturing concern Lonza reported a
decline in sales but net profit up by more than half in 2004,
although earnings came in at the low end of analysts' forecasts.
Lonza has commissioned a new current Good Manufacturing
Practice-compliant facility for the production of microbially
derived biopharmaceuticals at its largest worldwide production
centre in Visp, Switzerland.
Switzerland's Lonza Group said yesterday that it will use a novel
process developed by US-based biocatalysis company Codexis for the
synthesis of a key chiral pharmaceutical compound used in one of
the world's major human...
Lonza Biologics has licensed rights its proprietary CHOK1SV cell
line to Canadian firm Chromos Molecular Systems for a project aimed
at making improved mammalian cells for biological syntheses.
Lonza has signed two new agreements for the supply of monoclonal
antibody-based drugs that provide an early fillip for its contract
manufacturing business, which was adversely affected by
overcapacity in 2003.
A hoped-for recovery in the second half of 2003 failed to
materialise at Lonza, causing the chemicals and custom
manufacturing firm to post steep declines in sales and profits for
the full-year.
Switzerland's Lonza has won a long-term manufacturing contract from
US biotechnology bellwether Genentech for Rituxan (rituximab) a
biological drug which recorded worldwide sales of $1.48 billion in
2002.
The difficulties facing Lonza came into clear focus today as the
company published its half-year results, with sales down across its
custom manufacturing, organic chemicals and polymers businesses.
A deal with Vaccinex has taken Lonza Biologics beyond its primary
focus of mammalian cell culture-based manufacturing and into the
area of antibody drug discovery.
Swiss chemicals group Lonza has said that a new small-scale
production plant at its Visp site will come on stream in July and
will boost its services in the area of exclusive manufacturing of
pharmaceutical products.
Swiss life-science company Lonza announced on Tuesday that it is to
strengthen the production of oligonucleotides - an emerging new
class of therapeutics consisting of short nucleic acid chains
interfering in the processing of genetic...
